vimarsana.com

Latest Breaking News On - Actinium pharmaceuticals company profile - Page 1 : vimarsana.com

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Given Consensus Recommendation of "Buy" by Brokerages

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in […]

Creative-financial-designs-inc
Actinium-pharmaceuticals-trading
Institutional-trading-of-actinium-pharmaceuticals
Sanders-morris-harris
Cantor-fitzgerald
Actinium-pharmaceuticals
Analyst-recommendations-for-actinium-pharmaceuticals
News-ratings-for-actinium-pharmaceuticals-daily
Virtu-financial
Actinium-pharmaceuticals-inc
Maxim-group

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock […]

Cantor-fitzgerald
Creative-financial-designs-inc
Hedge-funds-weigh-in-on-actinium-pharmaceuticals
Analyst-recommendations-for-actinium-pharmaceuticals
Vanguard-group-inc
Actinium-pharmaceuticals
Brandywine-global-investment-management
Actinium-pharmaceuticals-stock-performance
Actinium-pharmaceuticals-company-profile
Virtu-financial
News-ratings-for-actinium-pharmaceuticals-daily

HC Wainwright Reaffirms Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. Several other research analysts also recently commented on ATNM. Cantor Fitzgerald reaffirmed an overweight rating […]

Actinium-pharmaceuticals-company-profile
Sanders-morris-harris
News-ratings-for-actinium-pharmaceuticals-daily
Maxim-group
Cantor-fitzgerald
Actinium-pharmaceuticals-inc
Creative-financial-designs-inc
Actinium-pharmaceuticals
Vanguard-group-inc
Virtu-financial
Actinium-pharmaceuticals-price-performance

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals […]

Vanguard-group-inc
Sanders-morris-harris
Institutional-investors-weigh-in-on-actinium-pharmaceuticals
Actinium-pharmaceuticals-company-profile
News-ratings-for-actinium-pharmaceuticals-daily
Cantor-fitzgerald
Actinium-pharmaceuticals
Creative-financial-designs-inc
Virtu-financial
Analyst-recommendations-for-actinium-pharmaceuticals
Actinium-pharmaceuticals-price-performance

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.